Woodline Partners LP Acquires New Holdings in ProQR Therapeutics (NASDAQ:PRQR)

Woodline Partners LP bought a new position in ProQR Therapeutics (NASDAQ:PRQR - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 3,557,001 shares of the biopharmaceutical company's stock, valued at approximately $9,426,000. Woodline Partners LP owned about 4.35% of ProQR Therapeutics as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently modified their holdings of PRQR. Affinity Asset Advisors LLC bought a new position in ProQR Therapeutics in the fourth quarter valued at $7,486,000. M&T Bank Corp bought a new position in ProQR Therapeutics during the fourth quarter worth $330,000. ArrowMark Colorado Holdings LLC acquired a new position in shares of ProQR Therapeutics in the fourth quarter valued at $3,131,000. XTX Topco Ltd acquired a new position in shares of ProQR Therapeutics in the fourth quarter valued at $163,000. Finally, Point72 Asset Management L.P. bought a new position in shares of ProQR Therapeutics in the fourth quarter valued at about $3,952,000. 32.65% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several equities analysts have recently commented on the company. Evercore ISI began coverage on ProQR Therapeutics in a research report on Tuesday, April 29th. They issued an "outperform" rating and a $5.00 target price on the stock. HC Wainwright increased their target price on shares of ProQR Therapeutics from $10.00 to $12.00 and gave the stock a "buy" rating in a research report on Friday, March 14th. Citigroup upgraded shares of ProQR Therapeutics from a "neutral" rating to a "buy" rating and set a $4.00 price target for the company in a research report on Monday, March 10th. Cantor Fitzgerald assumed coverage on ProQR Therapeutics in a research report on Tuesday, April 29th. They set an "overweight" rating and a $8.00 price target on the stock. Finally, Chardan Capital restated a "buy" rating and set a $4.00 price objective on shares of ProQR Therapeutics in a research note on Friday, March 14th. One equities research analyst has rated the stock with a sell rating, seven have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $8.00.

ProQR Therapeutics Trading Up 2.6%

ProQR Therapeutics stock traded up $0.04 during midday trading on Tuesday, reaching $1.71. The company's stock had a trading volume of 184,452 shares, compared to its average volume of 630,139. The stock has a market cap of $180.23 million, a PE ratio of -5.35 and a beta of 0.35. ProQR Therapeutics has a 52 week low of $1.07 and a 52 week high of $4.62. The business has a 50-day moving average price of $1.46 and a 200-day moving average price of $2.24.

ProQR Therapeutics (NASDAQ:PRQR - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, missing analysts' consensus estimates of ($0.09) by ($0.02). The company had revenue of $4.89 million during the quarter, compared to analyst estimates of $4.90 million. ProQR Therapeutics had a negative net margin of 134.31% and a negative return on equity of 71.58%. As a group, research analysts predict that ProQR Therapeutics will post -0.31 EPS for the current fiscal year.

ProQR Therapeutics Profile

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).